



ASX ANNOUNCEMENT

ANNUAL GENERAL MEETING

SYDNEY, Thursday 12 October 2017, Cellmid Limited (ASX: CDY) advises that in accordance with ASX Listing Rule 3.13.1 and Clause 46.3 of the Constitution, the Annual General Meeting of the Company will be held at 9.30am on Thursday, 23 November 2017 at BDO's Offices, Level 11, 1 Margaret Street, Sydney NSW 2000.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lynamid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lynamid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia, Japan and the USA and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au, www.evolisprofessional.com.au and www.evolisproducts.com.au.